Showing 1179 results
- https://www.novartis.com/news/media-releases/novartis-fuhrt-sms-life-20-nigeria-ein-um-den-zugang-zu-unentbehrlichen-arzneimitteln-zu-verbessern"SMS for Life 2.0" wird zum ersten Mal im Bundesstaat Kaduna, der bevölkerungsreichsten Region Nigerias, in Zusammenarbeit mit dem Gesundheitsministerium von Kaduna eingeführt. Das Programm nutzt…
- https://www.novartis.com/news/media-releases/novartis-provides-update-pegpleranib-phase-iii-clinical-trial-program-patients-neovascular-age-related-macular-degeneration-namd-or-wet-amdTwo pivotal Phase III studies did not show additional improvement in best corrected visual acuity (BCVA) for pegpleranib and Lucentis (ranibizumab) combination treatment over standard of care…
- https://www.novartis.com/news/media-releases/novartis-lee011-ribociclib-plus-letrozole-analyses-show-superior-pfs-across-broad-spectrum-patients-first-line-hrher2-advanced-breast-cancer-versus-letrozoleMONALEESA-2 analyses demonstrate superior PFS with LEE011 plus letrozole in pre-defined patient subgroups - from de novo to bone, liver and lung metastases - compared to letrozole alone …
- https://www.novartis.com/news/media-releases/novartis-ultibro-breezhaler-improved-lung-function-and-copd-symptoms-after-direct-switch-from-previous-treatmentUltibro® Breezhaler® improved lung function and breathlessness after direct switch from long-acting bronchodilators or steroid-containing combination therapies Results further support the…
- https://www.novartis.com/news/media-releases/novartis-receives-positive-chmp-recommendation-ilaris-treat-rare-diseases-adults-and-children-called-periodic-fever-syndromesPeriodic Fever Syndromes are rare diseases mostly affecting children[1] and cause recurrent and disabling fevers with potentially life-threatening complications[2] Ilaris® (canakinumab) is…
- https://www.novartis.com/news/media-releases/novartis-drug-votubia-recommended-chmp-eu-approval-treat-refractory-partial-onset-seizures-patients-tscIf approved, Votubia would be the first adjunctive treatment specifically for refractory seizures in children and adults with tuberous sclerosis complex (TSC)[1] Seizures are the most…
- https://www.novartis.com/news/media-releases/novartis-bolsters-innovative-dermatology-portfolio-through-acquisition-ziarco-group-limitedAcquisition to add a once-daily oral H4 receptor antagonist, ZPL389, to treat atopic dermatitis, commonly known as eczema, to the Novartis industry-leading pipeline Investigational…
- https://www.novartis.com/news/media-releases/novartis-launches-sms-life-20-nigeria-help-improve-access-essential-medicinesSMS for Life 2.0 launches for the first time in Kaduna State, Nigeria's third most populous region, in collaboration with the Kaduna State Ministry of Health Program uses smartphones and…
Novartis lance SMS for Life 2.0 au Nigeria pour aider à améliorer l'accès aux médicaments essentiels
https://www.novartis.com/news/media-releases/novartis-lance-sms-life-20-au-nigeria-pour-aider-ameliorer-lacces-aux-medicaments-essentielsSMS for Life 2.0 est lancé pour la première fois dans l'Etat de Kaduna, troisième région la plus peuplée du Nigeria, en collaboration avec le ministère de la Santé de l'Etat de Kaduna. Ce…- https://www.novartis.com/news/media-releases/novartis-receives-positive-chmp-opinion-first-line-use-zykadia-alk-positive-advanced-non-small-cell-lung-cancer-nsclcPhase III trial, first-line treatment with Zykadia resulted in improved progression-free survival (PFS) over SOC chemotherapy with maintenance, including in patients with brain metastases[1]…
Pagination
- ‹ Previous page
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- …
- 118
- › Next page